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Abstract 
Objective: To describe quality of life (QOL) over a 12-month period among women with 
breast cancer, consider the association between QOL and overall survival (OS), and explore 
characteristics associated with QOL declines. Methods: A population-based sample of 
Australian women (n=287) with invasive, unilateral breast cancer (Stage I+), was observed 
prospectively for a median of 6.6 years. QOL was assessed at six, 12 and 18 months post-
diagnosis, using the Functional Assessment of Cancer Therapy, Breast (FACT-B+4) 
questionnaire. Raw scores for the FACT-B+4 and subscales were computed and individuals 
were categorized according to whether QOL declined, remained stable or improved between 
six and 18 months. Kaplan-Meier and Cox proportional hazards survival methods were used 
to estimate OS and its associations with QOL. Logistic regression models identified factors 
associated with QOL decline. Results: Within FACT-B+4 sub-scales, between 10% and 23% 
of women showed declines in QOL. Following adjustment for established prognostic factors, 
emotional wellbeing and FACT-B+4 scores at six months post-diagnosis were associated with 
OS (p<0.05). Declines in physical (p<0.01) or functional (p=0.02) well-being between six and 
18 months post-diagnosis were also associated significantly with OS. Receiving multiple 
forms of adjuvant treatment, a perception of not handling stress well and reporting one or 
more other major life events at six months post-diagnosis were factors associated with 
declines in QOL in multivariable analyses. Conclusions:  Interventions targeted at preventing 
QOL declines may ultimately improve quantity as well as quality of life following breast 
cancer. 
 
Keywords: breast cancer; oncology; quality of life; survival 
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Introduction 
Five-year relative survival of women treated for breast cancer is approaching 90% for 
developed countries such as United States of America [1], Australia [2] and England [3]. In 
addition to survival, ensuring a good quality of life (QOL) following treatment is an important 
public health issue, as optimal QOL allows patients to sustain their usual roles in family, work 
and society. As such, QOL has become a popular primary outcome in breast cancer research, 
in conjunction with traditional endpoints, such as survival. 
 
For the majority of breast cancer survivors, QOL improves considerably during the first year 
following completion of treatment [4, 5]. However, for a subgroup of women, QOL has been 
reported to decline during this period [5, 6] and/or to remain at levels below that experienced 
by healthy peers [7, 8], with concerns such as arm dysfunction, lymphoedema and poor body 
image likely contributing [5, 9, 10]. 
 
Good QOL is important because it has been found to predict overall survival (OS) among 
patients with breast and other cancers [11-13]. Gotay and colleagues summarized clinical 
trials that assessed the relationship between QOL and survival [12]. These authors reported 
that despite a wide variety of QOL questionnaires, patient groups involved, and potential 
confounders considered, QOL seemed consistently to be a good predictor of OS, even after 
adjustment for performance status. However, patients included in clinical trials are commonly 
not representative of the broader cancer population. In addition, evidence of the QOL–
survival relationship appears consistent for all but early-stage breast cancer patients, for 
whom several studies failed to find an association between QOL and survival [14-18]. 
Reasons for this null finding may include the good overall survival of patients with early-
stage breast cancer and resulting low power to detect survival differences, strict inclusion 
criteria with resulting high homogeneity of clinical trial participants, and uncertainty or lack 
of clear definition of clinically significant QOL changes. Further, four of the five studies 
recruited women diagnosed in the 1980s or 1990s and may not reflect contemporary 
experiences of women with breast cancer [14-16, 18]. 
 
Our study updates this area of research as it provides results from a population-based, 
longitudinal cohort study of QOL among women diagnosed with breast cancer in 2002. 
Furthermore, in the breast cancer context, it represents the first study to investigate the 
potential prognostic significance of the Functional Assessment of Cancer Therapy (FACT) 
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instrument utilizing  predefined levels of clinical significance [19]. Hence the aims of this 
paper are to: 1) describe QOL over a 12-month period, from six- to 18-months post-diagnosis, 
among breast cancer survivors; 2) consider the association between QOL and OS; and 3) 
examine characteristics associated with QOL declines. 
 
Methods 
Ethical approval was obtained from a university human research ethics committee and access 
to patients followed the standard procedures of the local cancer registry. All women provided 
written, informed consent. 
 
Study Design and Sample Recruitment 
This study forms part of the Pulling Through Study, a longitudinal, population-based cohort 
study designed to track the physical and psychosocial recovery of women after breast cancer 
treatment [20, 21]. Details of the methods have been previously described elsewhere [22-24]. 
Briefly, an age-stratified (<50 years, 50+ years) sample of women newly -diagnosed with a 
first, primary, invasive, unilateral breast cancer in 2002, aged 74 years or younger, and who 
resided within 100 kilometers (i.e., 62 miles) of the capital city of Brisbane, Queensland, was 
randomly selected from the Queensland Cancer Registry. All cancer diagnoses in Queensland 
are required to be reported to the Registry; therefore these records provide an accurate 
sampling frame from which to recruit women who have been diagnosed recently (i.e., within 
six months of diagnosis) with breast cancer. 
 
Flow of women through the study is depicted in Figure 1. The Cancer Registry requires 
approval for contact of patients from the treating doctor, which was received for 87.2% 
(417/(511-33)) of potentially eligible women. In total, 287 (287/(511-35); 60.3%) women 
completed the baseline measure. As the study progressed to 12 and 18 months post-diagnosis, 
277 and 272 women, respectively, completed questionnaires. 
 
Data Collection 
Study participants completed a mailed, self-administered questionnaire assessing 
demographic characteristics (e.g., age, occupation, private health insurance), medical factors 
(e.g., treatment side, adjuvant therapy, complications following surgery), general health (e.g., 
weight, height, physical activity [25], upper-body function [26], stress, other major life 
events) and QOL status at six, 12, and 18 months post-diagnosis. 
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QOL was measured using a standardized, previously-validated instrument, the Functional 
Assessment of Cancer Therapy, Breast (FACT-B+4), which is comprised of 40 items rated on 
a five-point Likert scale ranging from 0=‘not at all’ to 4=‘very much’ [27]. The FACT-
General (FACT-G) section of the FACT-B+4 is calculated by summing subscales that assess 
four dimensions of QOL (physical, social, functional and emotional well-being). The FACT-
B+4, in addition, sums 13 breast cancer-specific concerns. All subscale and summary scores 
were calculated according to the FACT manual [28]. Higher scores represent better well-
being. The FACT-B+4 has been reported to have excellent internal consistency (alpha = 0.90) 
and test-retest reproducibility (r=0.85) [29]. As recommended by the developers of the FACT 
and other authors [19, 30], a mean difference over time or between groups of at least eight 
points on the FACT-B+4, five points on the FACT-G, three points for the breast cancer 
concerns, and two points for the other four subscales were considered minimum differences of 
clinical importance. 
 
Tumor characteristics were abstracted from histopathology reports at the Queensland Cancer 
Registry (e.g., type of surgery, maximum tumor size (mm), histology, grade and lymph node 
status). A death registry search on 15 April, 2009, determined vital status, date and cause of 
death, with surviving participants censored at this date. 
 
Statistical Analysis 
All analyses were performed using SPSS version 17 [31]. Women younger than 50 years at 
diagnosis were over-sampled to ensure adequate numbers for contrast with older women, 
therefore descriptive analyses were inversely weighted to reflect the original sampling frame. 
Age-adjusted mean QOL over time was estimated in repeated-measures regression analyses 
and reported with corresponding 95% CIs. 
 
To describe the patterns of change in QOL among survivors, women were classified, based on 
the clinical criteria for importance as noted above, according to whether their QOL declined, 
remained stable, or improved over time. Counts and proportions were calculated by change 
group for overall QOL and subscales. Mean QOL scores at 18 months were also calculated 
for each change category; as means for the ‘stable’ and ‘improved’ groups were not clinically 
different post-diagnosis, a dichotomous outcome variable combined these groups in order to 
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distinguish factors that influenced a decline in a woman’s QOL (declined vs. 
stable/improved). 
 
Mean survival times were calculated using the Kaplan-Meier technique and differences 
between QOL groups (declined vs. stable/improved) were assessed using the Log-rank test. 
The absolute mortality risk reduction between QOL groups was calculated by determining the 
difference between the percent of decliners who were alive at the censored date and the 
percent of stable/improvers alive at this time. Baseline (6 months post-diagnosis) overall QOL 
(continuous) and change in overall QOL between 6 and 18 months (dichotomous, contrasting 
decliners with stable/improved) were used when assessing the association of QOL with OS. A 
series of multivariable Cox regression models were performed to calculate hazard ratios (HR) 
and 95% CIs for association between OS and overall QOL, adjusted for baseline 
demographic, medical, general health and tumor characteristics. Reported is the model 
reduced to include only identified confounders of the association. After reduction, the final 
model was applied to calculate results for each QOL subscale. Underlying assumptions for 
these analytical techniques, including the absence of multi-collinearity and the proportional 
hazards assumption, were tested and met. Clinically important differences in QOL are 
highlighted throughout, and considered statistically-supported on attainment of the 
conventional p<0.05 level (two-tailed). 
 
To identify demographic, medical, general health and tumor characteristics associated with 
the categorized variable of decline in QOL between six and 18 months post-diagnosis, binary 
logistic regression analyses were conducted. All analyses were adjusted for age group (<50 
and 50+ years) as well as baseline QOL, to control for regression to the mean [32].  A 
difference in ORs of >1.8 or <0.6 were considered to be potentially important and worthy of 
highlighting here. 
 
Results 
In terms of both demographic and disease characteristics, the 287 participants were similar to 
those from the target sample (Table 1) [20, 21]. Average age of study participants was 55 
years (standard deviation=10) and the majority of women received complete local excision 
(73%), had some degree of lymph node dissection (87%) and were diagnosed with infiltrating 
ductal/not otherwise specified carcinoma (73%). Stage is not recorded in the Cancer Registry, 
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but from the available tumor size and node information, we extrapolated that more than half 
of the patients presented with early-stage disease (Stage 1, 55.7%). 
 
Median follow-up of the participants was 80 months (range 10-87 months) or 6.6 years. A 
total of 27 deaths were available for survival analyses; metastatic breast cancer was the 
recorded cause of death for 23 (85.2%) of the events, one (3.7%) death was due to cancer 
other than breast, and three (11.1%) women died due to non-cancer causes. 
 
Patterns of QOL 
Apart from the social and emotional wellbeing subscale scores, which remained constant 
across time, on average, age-adjusted means for overall QOL summary scores, as well as 
physical and functional subscales, increased between six and 12 months post-diagnosis 
(p<0.01), with no significant clinical change from this time to 18 months post-diagnosis 
(Table 2). Between 10%-23% of women reported a decline in QOL over the 12-month period 
(physical well-being=9.7%; social well-being=23.1%: emotional wellbeing=20.1%: 
functional well-being=18.1%: FACT-G=15.2% and FACT-B+4=10.4%). 
 
QOL at six months and survival 
Using Cox proportional hazards models, we assessed the unadjusted and adjusted associations 
between women’s QOL (continuous) at six months post-diagnosis and OS. Unadjusted 
analyses showed statistically significant associations between OS and physical well-being 
(HR=0.93; 95% CI: 0.88, 0.98; p=0.01), functional well-being (HR=0.92; 95% CI: 0.87, 0.98; 
p<0.01), FACT-G (HR=0.97; 95% CI: 0.94, 0.99; p<0.01) and FACT-B+4 (HR=0.98; 95% 
CI: 0.96, 0.99; p<0.01); that is, every one unit increase in QOL at six months post-diagnosis 
led to a statistically significant, 2%-8% reduced risk of death, depending on the QOL scale. 
After adjusting for age, socio-economic status (private health insurance, occupation), body 
mass index, and established prognostic (tumor size, overall grade, positive nodes) and 
treatment (hormone therapy) factors, the associations between OS and overall summary 
scores (FACT-G: HR=0.97; 95% CI: 0.94, 0.99; p=0.02; FACT-B+4: HR=0.98; 95% CI: 
0.96, 0.99; p=0.03) remained significant. In addition, a one-unit increase in the emotional 
well-being subscale score at six months post-diagnosis showed an 11% significantly reduced 
risk of death (HR=0.89; 95% CI: 0.81, 0.98; p=0.01). 
 
Change in QOL between six and 18 months and survival 
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When analysing change in QOL between six and 18 months post-diagnosis, women who 
reported that their overall QOL (FACT-B+4) declined during this time survived for an 
average of 79.8 months (95% CI: 73.4, 86.2) compared with 83.5 months (95% CI: 82.0, 
85.1) among women who reported that their QOL remained stable/improved over the 12-
month period (p=0.35) (Table 3). This corresponds with an absolute mortality risk reduction 
of 4.9% for women with stable or improved QOL at the end of follow-up. Within the QOL 
subscales, women who reported a decline in physical or functional well-being experienced a 
lesser mean survival time of 4.7 months (p=0.08) and 3.4 months (p=0.10), respectively, 
compared with women who reported that their physical or functional well-being remained 
stable/improved; this equates to an absolute mortality risk reduction of 10.0% and 7.3%, 
respectively, at the end of follow-up. Smaller differences in mean survival times between 
groups for the other QOL scales were observed (Table 3). 
 
Unadjusted analyses showed that the HR of death was decreased for women experiencing 
stable or improving physical (HR=0.43; 95% CI: 0.16, 1.14; p=0.09), emotional (HR=0.49; 
95% CI: 0.22, 1.09; p=0.08) or functional (HR=0.50; 95% CI: 0.22, 1.15; p=0.10) well-being, 
although results were not statistically significant. Following adjustment for confounding 
variables, the decreased risk of death was sustained and became statistically significant for 
physical (HR=0.24; 95% CI: 0.08, 0.70; p<0.01) and functional (HR=0.35; 95% CI: 0.14, 
0.87; p=0.02) well-being. Adjusted results also showed that the HR of death was decreased 
for women with stable or improved QOL on the FACT-B+4 overall scale (HR=0.43; 95% CI: 
0.14, 1.31; p=0.14), although this was not statistically significant (Table 3). 
 
Predictors of decline in QOL 
Compared to women who reported stable or improved QOL, women reporting a decline in 
QOL were more likely to be older than 50 years of age (OR=1.84; 95% CI: 0.65, 5.27; 
p=0.25), treated by both radiotherapy and chemotherapy (OR=2.73; 95% CI: 0.72, 10.4; 
p=0.14), report poorer than most upper-body function (OR= 1.83; 95% CI: 0.64, 5.10; 
p=0.34), report a lower perception of handling stress well (OR=6.16; 95% CI: 1.58, 24.0; 
p=0.009), and were more likely to have experienced one or more non-cancer related major life 
events (OR=4.60; 95% CI: 1.01, 20.9; p=0.05) at six months post-diagnosis (Table 4). 
 
Discussion 
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On average, the QOL of women enrolled in this cohort study improved over time. However, 
up to one in four women experienced clinically important declines in QOL between six and 
18 months after a diagnosis of breast cancer, highlighting the varied experiences of these 
women. Two previous studies similarly reported that a significant subgroup (10-12%) of 
women report declines in well-being after treatment for breast cancer [5, 6]. Declines in 
physical, functional and overall QOL increased the risk of death (statistically significant 
results for physical and functional well-being, but not for overall quality of life). The mean 
survival time was 83.5 months among stable/improvers compared to 79.8 months among 
those whose QOL declined by eight points or more on the FACT-B+4, an absolute survival 
difference of 4.9% at 6.6 years (range 0.83-7.25 years) following diagnosis. A reduction in 
death of 4% or more at five-years post-diagnosis is of the magnitude consistent with the 
survival benefits accrued through chemotherapy [33]. 
 
An assessment of decline in QOL can only be conducted accurately using longitudinal data. 
When QOL was assessed and categorized in this manner, the majority of studies reported an 
association between QOL and survival [12]. Five previous studies used a FACT questionnaire 
specifically [34-38]. Compared to our study (HR=0.24-0.88), the magnitude of risk reductions 
through good QOL observed in these studies was similar in two (HR=0.69 and HR=0.76) and 
less pronounced in three studies (HR=0.91-0.95): however, all of these studies were 
conducted with patients with advanced cancer and none included patients with breast cancer. 
 
Comparison of the current study with much of the breast cancer QOL and survival literature is 
difficult because of differences in study design, changes in diagnosis and treatment over time 
(the majority of previous studies recruited women diagnosed in the 1980s or 1990s) [14-16, 
18], study sample restrictions (exclusions based on the existence of other medical conditions 
or use of certain medications [15], age <60 at diagnosis [18], node-negative tumors [14], prior 
focus on women with advanced stage breast cancer) [17], timing of data collection (initial 
assessment of QOL pre-treatment [15], two months post-treatment [16], up to 11 months post-
diagnosis [18]), statistical analysis (QOL used continuously or categorized in a variety of 
ways) and the QOL instrument used (EORTC [15, 16], HADS [18], QLI [17], LASA [14]). 
Further, results from these published studies are inconsistent, and although five studies 
included women diagnosed with early-stage breast cancer, only two focused exclusively on 
women diagnosed with a primary, invasive breast cancer of grade I to III, where exclusions 
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were not based on age or treatment [15, 16]. As such, these latter two studies represent the 
most relevant previous work against which to compare our findings. 
 
Unlike our population-based recruitment approach, these two studies, one being a Canadian 
study [15], the other a study on Danish women [16], recruited clinic-based samples of 397 
and 1,588 women, respectively, with both cohorts diagnosed with breast cancer between 1991 
and 1996. In contrast to our work, which showed a statistically significant, inverse association 
between QOL at six months and OS at an average of 6.6 years follow-up, results from the 
Canadian study concluded that QOL (measured via the EORTC) at diagnosis and one year 
later (based on comparing the 25th and 75th percentiles) were not associated with OS at an 
average of 5.8 years follow-up [15].  Similar to our results, the Danish study, which involved 
a longer follow-up period (approximately 13 years follow-up) when compared with ours and 
the Canadian study, concluded that better emotional functioning (measured via the EORTC 
and dichotomized at the median) was associated with better OS [16]. Also in line with 
findings from the Danish study [16], the subscales that contributed most to the decline in 
overall QOL observed in our study were social (23.1%) and emotional (20.1%) well-being. 
Women who were more likely to report a decline in overall QOL included those who were 
feeling that they did not handle stress well or experienced other life events in combination 
with their cancer diagnosis. 
 
If better QOL during the early survivorship phases (6-18 months post diagnosis) reduces the 
risk of death, then psychosocial interventions or those directed at improving QOL could 
prolong life. A meta-analysis of the effects of psychosocial interventions on survival time in 
cancer patients concluded that the “matter is not resolved”, but did report that individual 
treatments may work over group interventions (7 out of 14 interventions were conducted with 
local, regional or distant breast cancer) [39]. Other work suggests that support may not be 
beneficial for all cancer patients and should be offered to those in need for additional support 
only [40]. It has been further discussed that people with well-developed coping skills or high 
self-efficacy may be disrupted in their own personal and favorable coping if provided with an 
intervention [40, 41]. Targeting of interventions towards individual needs and skills therefore 
seems critical. 
 
Our work also indicates that those with poorer than average upper-body function or reduced 
perceived handling of stress experience increased risk of declines in QOL. While the 
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relationship observed in this study between being physically active and reduced risk of QOL 
declines demonstrated only borderline clinical importance, results in the literature indicate 
that physical activity may play a key role in minimizing treatment-related side effects 
(including reduced upper-body function and distress) and optimizing women’s QOL [42], and 
three large cohort studies provide evidence for beneficial survival effects of post-diagnosis 
physical activity [43-45]. However, to date, no trial has attempted to improve OS among 
women with breast cancer through a physical activity intervention, potentially because a large 
number of women would need to be enrolled to show a survival effect. 
 
Limitations of the present study are those typically associated with cohort studies, with 
confounding variables which were not measured or unknown, potentially responsible for the 
associations identified. Also, recruitment following the Cancer Registry procedures led to 
exclusion of those women deemed ineligible by the treating doctor. However, doctors would 
have been more likely to exclude women with lower QOL than higher QOL, which would 
suggest that our results most likely reflect conservative estimates. We were able to compare 
our participants to the target sample on a number of important personal and clinical 
characteristics (but not QOL) and have shown that selection bias is unlikely to have played a 
major role in our analysis. The number of patients with declining QOL and the number of 
deaths were low, making it necessary to be cautious about the certainty associated with our 
findings. This is reflected in wide confidence intervals. However, the associations between 
QOL and OS were consistent in direction, regardless of subscale and whether QOL was 
assessed in a continuous or categorical (decline versus stable/improve) fashion. 
 
Strengths of our study include its population-based and prospective design; thus results are 
likely to be generalizable to the larger population of women recently diagnosed with 
unilateral, primary, invasive breast cancer, and reflecting current treatment. Further, QOL was 
measured via the FACT, a reliable QOL instrument with good support for its validity [29], 
and relationships with OS were controlled for known prognostic factors. Nonetheless, large-
scale survival studies with the collection of a wider range of potentially modifiable risk 
factors are needed to advance this area of research. If the association between QOL and OS in 
early-stage breast cancer is confirmed, future RCTs of treatments may consider stratifying 
based on baseline QOL. Women who show early declines in QOL may benefit from 
additional support, especially if they perceive themselves as not coping well or they are not 
physically active. 
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Conclusion 
Our findings indicate that interventions aimed at maintaining or improving QOL following 
breast cancer diagnosis and treatment remain important to a woman’s quantity as well as 
quality of life. Interventions should be targeted towards individual women’s needs or 
perceived weaknesses, whether in the physical or psychosocial domains. 
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Table 1. Demographic and clinical characteristics of the target sample and study participants 
 
 
Target samplea 
%
Study participantsb 
% 
Total  511 287 
Age (years) 
 Mean (+ standard deviation)  
 
54 (10) 
 
55 (10) 
Most extensive surgery 
 Complete local excision 
 Mastectomy  
 
72.2 
27.8 
 
72.5 
27.5 
Largest tumor size (mm) 
 Median (range)  
 
14 (0.3-230) 
 
14 (0.5-140) 
Lymph node dissection 
 Yes 
 Number of nodes examined 
  Median (range) 
 Number of positive nodes 
  Median (range)  
 
86.3 
 
12 (1-47) 
 
0 (0-39) 
 
86.7 
 
12 (1-47) 
 
0 (0-39) 
Overall histological grade 
 1 
 2 
 3 
 Unavailable  
 
24.3 
35.7 
32.2 
7.8 
 
26.6 
31.8 
30.6 
11.0 
Histological type 
 Infiltrating/ductal/NOS carcinoma 
 Tubular/cribriform carcinoma 
 Medullary/mucinous/colloid adenocarcinoma 
 Infiltrating lobular 
 Other mixed type  
 
78.2 
3.9 
0.8 
12.4 
4.7 
 
72.5 
5.2 
0.3 
15.7 
6.4 
Notes: 
(a) Target sample refers to the age-stratified, random sample obtained from the pool of all women diagnosed 
with breast cancer in the population-based Queensland Cancer Registry after application of eligibility 
criteria. 
(b) Results presented have been appropriately weighted (<50 years, 1.0; >50 years, 1.3) for oversampling of 
younger women. 
Abbreviations:  
NOS, not otherwise specified. 
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Table 2. QOL at six, 12 and 18 months post-diagnosis 
FACT subscales (range)a 
6 months  12 months  18 months  Differences over time 
n Mean (95% CI)  n Mean (95% CI)  n Mean (95% CI)  p value clinicalb 
Physical well-being (0-28) 269 22.7 (22.1, 23.3)  269 24.6 (24.2, 25.1)  269 24.8 (24.3, 25.2)  <0.01  
Social well-being (0-28) 266 22.8 (22.2, 23.5)  266 22.7 (21.9, 23.4)  266 22.7 (22.0, 23.4)  0.42  
Emotional well-being (0-24) 239 19.1 (18.6, 19.5)  239 19.8 (19.3, 20.3)  239 19.7 (19.3, 20.2)  <0.01  
Functional well-being (0-28) 268 20.8 (20.1, 21.5)  268 22.3 (21.8, 22.9)  268 22.3 (21.7, 22.9)  0.01  
Breast cancer concerns (0-52)  268 37.8 (37.0, 38.7)  268 40.1 (39.3, 41.0)  268 40.4 (39.6, 41.3)  <0.01  
FACT-G (0-108) 252 85.4 (83.6, 87.2)  252 89.5 (87.8, 91.2)  252 89.7 (88.0, 91.4)  <0.01  
FACT-B+4(0-160) 260 123.6 (121.2, 126.0)  260 129.9 (127.6, 132.2)  260 130.3 (128.0, 132.6)  <0.01  
Notes: 
(a) Higher scores indicate better well-being; adjusted for age. 
(b) : clinically meaningful difference between groups (two+ points for physical, social, emotional, and functional well-being; three+ points for breast cancer concerns; 
five+ points for FACT-G, eight+ points for FACT-B+4); : no clinically meaningful difference between groups. 
Abbreviations: 
FACT-G: Functional Assessment of Cancer Therapy-General; FACTB+4: Functional Assessment of Cancer Therapy-Breast additional four questions; : clinically 
meaningful change; : no clinically meaningful change. 
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Table 3. Mean overall survival time for change in QOL between six and 18 months post-diagnosis 
   Kaplan Meier 
estimates 
Log rank 
test 
Multivariable Cox regression 
Change in FACT subscalesa Total n N  Mean survival (95% CI) 
Months 
p valueb HRcd (95% CI) p value 
  events     
Physical well-being 
 Stable/Improve 
 Decline  
 
260 
27 
 
22 
5 
 
83.6 
78.9 
 
(82.1, 85.1) 
(72.1, 85.7) 
 
0.079 
 
0.24 
1.00 
 
(0.08, 0.70) 
- 
 
<0.01 
Social well-being 
 Stable/Improve 
 Decline  
 
219 
68 
 
18 
9 
 
83.4 
82.6 
 
(81.6, 85.2) 
(79.7, 85.6) 
 
0.21 
 
0.59 
1.00   
 
(0.25, 1.41) 
- 
 
0.24 
Emotional well-being 
 Stable/Improve 
 Decline  
 
230 
57 
 
18 
9 
 
83.6 
81.8 
 
(81.9, 85.3) 
(79.1, 85.6) 
 
0.074 
 
0.54 
1.00 
 
(0.23, 1.26) 
- 
 
0.15 
Functional well-being 
 Stable/Improve 
 Decline  
 
235 
52 
 
19 
8 
 
83.7 
80.3 
 
(82.0, 85.3) 
(79.2, 84.5) 
 
0.095 
 
0.35 
1.00 
 
(0.14, 0.87) 
- 
 
0.02 
Breast cancer concerns 
 Stable/Improve 
 Decline 
 
244 
43 
 
23 
4 
 
83.0 
83.4 
 
(81.3, 84.8) 
(80.1, 86.6) 
 
0.97 
 
0.88 
1.00 
 
(0.28, 2.78) 
- 
 
0.82 
FACT-G 
 Stable/Improve 
 Decline  
 
244 
43 
 
22 
5 
 
83.5 
81.0 
 
(81.8, 85.1) 
(76.5, 85.6) 
 
0.55 
 
0.80 
1.00 
 
(0.29, 2.20) 
- 
 
0.67 
FACT-B+4 
 Stable/Improve 
 Decline  
 
258 
29 
 
23 
4 
 
83.5 
79.8 
 
(82.0, 85.1) 
(73.4, 86.2) 
 
0.35 
 
0.43 
1.00 
 
(0.14, 1.31) 
- 
 
0.14 
Notes: 
(a) Change in QOL between 6 and 18 months post-diagnosis based on clinically meaningful differences (two+ points for physical, social, emotional and 
functional well-being, three+ points for breast cancer concerns, 5+ points for FACT-G, eight+ points for FACT-B+4). 
(b) Log-rank p value. 
(c) HR = hazard ratio; HR<1 indicates a reduced risk of death. 
(d) Adjusted for the QOL scales shown in the row, as well as age (continuous), private health insurance (yes, no), body mass index (underweight/normal 
weight/missing, overweight, obese), tumour size (<16mm, 16+mm), overall grade (one, two/three/not available), positive nodes (none removed, none invaded, 
1+ invaded), hormone therapy (yes, no) and baseline. 
Abbreviations: 
FACT-G: Functional Assessment of Cancer Therapy-General; FACTB+4: Functional Assessment of Cancer Therapy-Breast additional four questions. 
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Table 4. Multivariable associations for a decline in QOL (FACT-B+4) between six and 18 
months post-diagnosis and characteristics at baseline 
Characteristic at baselinea  Multivariable Model
b 
 n OR (95% CI) p value 
Age (years) 
 <50 
 50+  
 
 93 
 190 
 
1.00 
1.89 
 
- 
(0.66, 5.45) 
0.23 
Income 
 $52,000+ 
< $52,000 
Missing  
 
 94 
 157 
 32 
 
1.00 
1.57 
0.43 
 
- 
 (0.62, 3.99) 
(0.08, 2.36) 
0.19 
 
 
Adjuvant treatment 
 None 
 Radiotherapy or chemotherapy  
     Both  
 
 45 
 154 
 84 
 
1.00 
1.00 
2.74 
 
- 
(0.30, 3.37) 
(0.72, 10.4) 
0.55 
 
 
Total physical activityc 
 Sedentary 
 Active  
 
 48 
 235 
 
1.00 
0.65 
 
- 
(0.21, 1.96) 
0.44 
 
 
Upper-body functiond 
 Good function (11+) 
 Poor function (<11) 
 Missing  
 
 129 
 127 
 27 
 
1.00 
1.82 
2.48 
 
- 
(0.64, 5.16) 
(0.64, 9.77) 
0.34 
 
 
Perceived handling of stress 
 Very well 
 Fairly well to not well at all  
 
 66 
 217 
 
1.00 
6.16 
 
- 
(1.58, 24.0) 
0.009 
Major life events 
 None 
 One or more   
 
 63 
 220 
 
1.00 
4.60 
 
- 
(1.01, 20.9) 
0.05 
 
 
Notes: 
(a) Measured at six months post-diagnosis. 
(b) Odds ratio of a decline in QOL over a 12-month period; Odds ratio mutually adjusted for QOL at baseline 
all other variables in the model; Nagelkerke R2=0.19. 
(c) ‘Total physical activity’ = vigorous + moderate activities. 
(d) Upper-body function was classified as ‘missing’ if insufficient items were completed for a score to be 
calculated. 
 
